Filing Flows › Biofrontera (BFRI) › Q4 2024
Biofrontera (BFRI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Biofrontera (BFRI) reported revenue of $12.6M for the fourth quarter 2024 (Q4 2024), +19% from a year earlier and +39% from the quarter before. Operating margin was -13.6%, net loss $1.4M (11.1% of revenue).
Biofrontera, Q4 2024: revenue $12.6M (+18% year over year), operating margin -13.6%, net loss $1.4M, operating cash flow −$1.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.6M | +39% | +19% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$1.0M | — | — |
What changed
Revenue was $12.6M in Q4 2024, up 19% year over year and up 39% from the previous quarter.
Operating costs exceeded revenue by $1.7M, an operating margin of -13.6%. Total costs fell 1% while revenue rose 19%. The fastest-growing cost line was Research & development (+2273%). The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $5.7M loss. Non-operating items added $313K, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.0M. Non-cash charges added back $34K of depreciation and amortization and $299K of share-based compensation. Capital expenditures of $1K exceeded it, leaving free cash flow of −$1.0M.
Questions
What was Biofrontera's revenue in the fourth quarter 2024?
Biofrontera (BFRI) reported revenue of $12.6M for the fourth quarter 2024 (Q4 2024), +19% from a year earlier and +39% from the quarter before.
Was Biofrontera profitable in the fourth quarter 2024?
Operating loss was $1.7M (-13.6% of revenue) and net loss $1.4M.
Source: Biofrontera 10-K on SEC EDGAR.